
    
      The duration of the study for an individual patient will include a period to assess
      eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1
      cycle (3 weeks or 4 weeks depending on regimen) of study treatment, and an end-of-treatment
      visit at least 30 days following the last administration of study drug. However, treatment
      may continue until precluded by toxicity, progression, or death.
    
  